Authors

1. Aschenbrenner, Diane S. MS, RN

Abstract

* The labeling of omalizumab (Xolair), a drug used to treat allergic asthma, now carries a warning that its use may slightly increase the risk of cardiovascular complications. The drug may also pose an increased risk of inducing cancer.